Oncolytics Biotech (ONCY) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ONCY filings

Are insiders buying or selling Oncolytics Biotech Inc (ONCY) stock?

Neither. Oncolytics Biotech Inc (ONCY) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ONCY recently?

None. No member of Congress disclosed a ONCY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ONCY smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

8 funds hold a position.

Questions about ONCY filings

Are insiders buying or selling Oncolytics Biotech Inc (ONCY) stock?

Neither. Oncolytics Biotech Inc (ONCY) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ONCY recently?

None. No member of Congress disclosed a ONCY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ONCY smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 11, 2026

Earnings came in $0.04 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 11, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.10-$0.04 miss

-$0.06 expected

Revenue (FY)

CAD 0.00

Year ended Dec 31, 2024 · SEC filing · No operating revenue

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 11, 2026	-$0.10est. -$0.06	-$0.04miss	Not on file	Not on file
Jun 30, 2026Reported Aug 12, 2026	Not on file	No estimate	Not on file	Not on file
Mar 31, 2026Reported May 14, 2026	-$0.11est. -$0.07	-$0.04miss	Not on file	Not on file
Dec 31, 2025Reported Mar 30, 2026	$0.00est. -$0.07	+$0.07beat	Not on file	Not on file
Sep 30, 2025Reported Nov 12, 2025	-$0.14est. -$0.07	-$0.07miss	Not on file	Not on file
Jun 30, 2025Reported Aug 8, 2025	-$0.07est. -$0.08	+$0.01beat	Not on file	Not on file
Mar 31, 2025Reported May 14, 2025	-$0.08est. -$0.09	+$0.01beat	Not on file	Not on file
Dec 31, 2024Reported Mar 7, 2025	-$0.10est. -$0.13	+23.08%beat	CAD 0.00 · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $0.41
High: $0.42
Low: $0.37
Prev close: $0.41
52-wk high: $1.30
52-wk low: $0.37
Mkt cap: $54.0M
ROE: -769.0%
Fwd P/E: 45.5x
Beta: 1.24
P/S: 58.6x
P/B: 32.9x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 45.45
Market cap: $54M

Valuation

P/S58.60
P/B32.88

Quality

Operating margin0.0%
ROE-769.0%
ROA-211.2%

Growth

Beta1.24

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

29oversold

20D volatility

82%annualized

52-week range

$0.37

$0.37$1.30

20D support

$0.37recent floor

20D resistance

$0.55recent ceiling

Returns

5D -17.1%20D -32.1%60D -55.2%

Price vs moving averages

SMA20 -16.5%SMA50 -36.7%SMA200 -55.3%

Volume pace

0.67xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 11, 2026

-$0.10est. -$0.06

-$0.04

Not on file

Jun 30, 2026Aug 12, 2026

Not on file

No estimate

Not on file

Mar 31, 2026May 14, 2026

-$0.11est. -$0.07

-$0.04

Not on file

Dec 31, 2025Mar 30, 2026

$0.00est. -$0.07

+$0.07

Not on file

Sep 30, 2025Nov 12, 2025

-$0.14est. -$0.07

-$0.07

Not on file

Jun 30, 2025Aug 8, 2025

-$0.07est. -$0.08

+$0.01

Not on file

Mar 31, 2025May 14, 2025

-$0.08est. -$0.09

+$0.01

Not on file

Dec 31, 2024Mar 7, 2025

-$0.10est. -$0.13

+23.08%

CAD 0.00 · FYSEC filing

No year-ago quarter

Oncolytics Biotech Inc

Smart money at a glance

What do analysts expect?

Questions about ONCY filings

Questions about ONCY filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.04 a share below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Oncolytics Biotech Inc

Smart money at a glance

What do analysts expect?

Questions about ONCY filings

Questions about ONCY filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.04 a share below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Oncolytics Biotech Inc

Overview

Questions about ONCY filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Oncolytics Biotech Inc

Overview

Questions about ONCY filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.